Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-L1 antibody plus neoadjuvant chemoradiotherapy in locally advanced rectal cancer (Phase II, open-label RCT)
ChiCTR2500111728Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in rectal cancer (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Pathologic complete response (pCR). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR2500111728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111728.